Parkinson’s Drugs & Impulsive Behaviour Making Headlines Again

This isn’t entirely new—but it's making waves again in the news and worth sharing. Certain dopamine agonists, used to treat Parkinson’s disease and Restless Legs Syndrome (RLS), have been repeatedly linked to serious impulse control disorders—including pathological gambling, hypersexuality, compulsive shopping, and binge eating. Medicines That Move Muscles – and Sometimes Impulses When you’re diagnosed with Parkinson’s Disease or Restless Leg Syndrome, your doctor may prescribe a dopamine agonist – a drug that mimics dopamine to help regulate movement. And in many cases, these drugs work really well. They can reduce tremors, calm restless legs, and improve quality of life. But here’s the problem: some of these medications have been linked to a deeply troubling side effect – impulsive, risky, and even self-destructive behaviour. And it’s not just theory. Over the last two decades, a growing body of patient stories, medical warnings, and legal cases has painted a much darker picture of what these treatments can trigger – including compulsive gambling, binge eating, risky sexual activity, and massive debt. The Drugs in Question The medications most often linked to these behaviours are dopamine agonists prescribed for PD and RLS. These include: Ropinirole (ReQuip) Pramipexole (Mirapex) Cabergoline (Cabaser) Bromocriptine Rotigotine (Neupro) They act by stimulating dopamine receptors in the brain – the same reward pathways that light up when we experience pleasure. But in some people, that stimulation can go into overdrive. How This Shows Up in Real Life These aren't just rare, one-off side effects. Studies have shown that: Between 6% and 17% of RLS patients on dopamine agonists may develop an impulse control disorder. Up to 1 in 5 people with Parkinson’s may be affected. But the true number could be higher, because many people are too ashamed to talk about it – or don’t realise the medication is the cause. BBC investigations and medical reviews have detailed heartbreaking real-life examples: 👉 Claire’s Story Claire, prescribed ropinirole for RLS, began experiencing uncontrollable sexual urges. She would leave home in the middle of the night, exposing herself to strangers, despite knowing something felt wrong. When she finally stopped the medication, the urges vanished. But the emotional scars remain. 👉 Sue’s Story Sue was never warned about side effects. She developed a gambling addiction after starting dopamine agonists and racked up £80,000 in debt before she realised it was linked to her meds. Her family was devastated. 👉 Sarah’s Story Sarah, previously disinterested in sex, found herself selling explicit videos and used underwear online, compulsively shopping, and eventually entering rehab. Her story, too, only made sense in hindsight – once the drug was stopped. And it’s not just women. One French man, after taking ropinirole, began exhibiting “deviant behaviour” including torturing animals. Another sexually assaulted a child. These tragic events were directly linked in internal pharmaceutical company reports to the medication. Legal Fallout & Pharmaceutical Response Several lawsuits have been filed against pharmaceutical giants: In 2012, a French court ordered GlaxoSmithKline to pay damages to a man whose life was upended by compulsive behaviours triggered by ReQuip. In 2014, Pfizer settled a class action in Australia involving over 150 people taking Cabaser. In the UK, a class action against GSK in 2011 alleged that warnings about compulsive behaviours were delayed by several years – despite early evidence in 2000. Although patient leaflets now include general warnings about “altered sexual interest” or “impulse control disorders,” specific and severe outcomes like risky sex or gambling addiction are often not clearly explained. Why It’s Back in the News These reports aren’t new – but they’ve resurfaced due to recent BBC investigations and new academic concern. Internal documents from GSK as far back as 2003 mention “deviant sexual behaviour” and links to criminal cases, but patients say they were never warned. Researchers and neurologists now stress that these medications must be prescribed with clear, honest discussions about risk – especially for women and younger patients, who may be more vulnerable. What You Need to Know If you or a loved one is taking a dopamine agonist: ✅ Know the risks: Be aware of impulse control issues, even if they sound “out of character.” ✅ Watch for changes: Compulsive shopping, gambling, or unusual sexual behaviour can creep in slowly – and may be the drug, not you. ✅ Talk to your doctor: Most behaviours stop once the drug is reduced or stopped. Don’t suffer in silence. ✅ Stay monitored: Especially after dosage changes or if symptoms seem to worsen. ✅ Not everyone is affected: These drugs are important treatments, and many people benefit without issue. But for those who do experience problems, early recognition is key.